Friday, 03 Apr 2020

You are here

Which Biologics are Best in Psoriasis

A metanalysis of phase II, III and IV trials in moderate to severe plaque psoriasis suggests comparative efficacy biologic treatments, but that that brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa were shown to have the past skin (PASI) response rates.

The meta-analysis included 60 clinical trials for short-term (up to 16 weeks) and long-term (44-60 weeks) efficacy with  brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa. Moderate to severe psoriasis was assessed by the Psoriasis Area and Severity Index assessment of 75%, 90%, and 100% responses.

 

From weeks 10 to 16, the highest PASI 90 rates were seen with

  • risankizumab-rzaa (71.6%)
  • brodalumab (70.8%)
  • ixekizumab (70.6%)
  • guselkumab (67.3%)

From weeks 44 to 60, the PASI 90 rates were:

  • risankizumab-rzaa (79.4%)
  • guselkumab (76.5%)
  • brodalumab (74.0%)
  • ixekizumab (73.9%)

These data show high level, comparative efficacy with IL-17 and IL-23 targeted biologics in moderate to severe plaque psoriasis.

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

No Cancer Increase in Psoriatic Arthritis or with Biologics in Psoriasis

JAMA Dermatology reports that psoriasis is associated with a slightly increased risk of cancer, particularly keratinocyte cancer and lymphomas.

A systematic review and meta-analysis of 112 studies including more than 2 million patients, also shows no increase in when psoriasis is treated with biologic agents, nor was psoriatic arthritis associated with an increased risk of cancer.   

Bimekizumab Effective in Active Psoriatic Arthritis

Interleukin 17 IIL-17) is important in the pathogenesis of psoriatic disease, with most current approaches targeting IL-17A. Now there is a noveal approach showing that dual neutralisation of IL-17A and IL-17F in psoriatic arthritis arthritis patients results in clinically significant improvement.

Upadacitinib Effective in Phase 3 Psoriatic Arthritis Study

Abbvie has announced top line results of their SELECT-PSA trial of upadacitinib (UPA), wherein both the 15 and 30 mg doses met the primary endpoint of ACR20 response at week 12 and demonstrated radiographic inhibition at week 24.

Taltz Shines in Non-Radiographic Axial Spondyloarthritis

Ixekizumab (IXE), an interleukin-17A (IL-17A) inhibitor, was recently approved for use in ankylosing spondylitis (also known as radiographic axial spondyloarthritis- axSpA). Lancet has published the results of the COAST-X study showing that ixekizumab was effective in patients with non-radiographic axial spondyloarthritis.

Best of 2019 - SEAM-PsA Study - Does Monotherapy MTX Win Despite Losing to Etanercept in Psoriatic Arthritis?

The SEAM-PsA study examined the efficacy of methotrexate monotherapy, etanercept monotherapy or the combination of MTX and ETN in psoriatic arthritis patients, and found that ETN monotherapy was equivalent to combination therapy - and that both were superior to MTX alone in clinical (ACR and MDA) and radiographic responses.